摘要
在最重要的生理功能中,细胞氧化还原平衡的维持是一个主要的稳态事件。许多环境污染物有效的套住了细胞还原化合物,但是这种毒性模式的实际重要性还远不为人所知。这种情况出现在一些慢性发展的长期疾病案例中,如神经退行性病,糖尿病和许多其他的疾病。糖尿病中氧化困难的介入被认为与长期 饮食暴露于低浓度镉有关联。与多氯联苯分子(PCB)比较:他们在结构上与镉无关联,他们比镉优先分配到不同的器官,他们遵从不同的代谢途径。然而,他们也有促氧化性质,他们与糖尿病有联系。既然镉和多氯联苯都不是准确的氧化剂,他们都遵循不同的方式来移动氧化还原平衡。因此,机体的适应性反应一定会产生差别,如抗氧化反应,氧化物种产生的不可逆损伤,又如,当暴露在低浓度时发生的氧化损伤。从可用的相关数据中预计了暴露的高低浓度的大概界线,并阐述了实验模型的强弱度。最终,长期暴露于低浓度的污染物中造成功能失调和疾病的细胞反应前兆,例如糖尿病:氧化损伤是一个伴随现象且在毒性的早期机制中是不必要的。
关键词: 镉,糖尿病,胰岛素,氧化应激,多氯联苯化合物,低剂量,生物标记物,风险评价
Current Drug Targets
Title:Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Volume: 17 Issue: 12
Author(s): Adeline Jacquet, Fayçal Ounnas, Marine Lénon, Josiane Arnaud, Christine Demeilliers, Jean-Marc Moulis
Affiliation:
关键词: 镉,糖尿病,胰岛素,氧化应激,多氯联苯化合物,低剂量,生物标记物,风险评价
摘要: Among the most important physiological functions, maintenance of the oxidation reduction equilibrium in cells stands out as a major homeostatic event. Many environmental contaminants efficiently trap cellular reducing compounds, but the actual importance of this mode of toxicity is far from being precisely known. This statement applies to cases of slowly developing chronic diseases, such as neurodegenerations, diabetes, and many others. The involvement of oxidative challenge in diabetes is considered in connection with chronic dietary exposure to low-level concentrations of cadmium. Comparison is made with polychlorobiphenyl molecules (PCB): they are structurally unrelated to cadmium, they preferentially distribute into different organs than cadmium, and they follow different metabolic pathways. Yet, they have also pro-oxidative properties, and they are associated with diabetes. Since neither cadmium nor PCB is a direct oxidant, they both follow indirect pathways to shift the redox equilibrium. Thus, a difference must be made between the adaptable response of the organism, i.e. the anti-oxidant response, and the irreversible damage generated by oxidizing species, i.e. oxidative damage, when exposure occurs at low concentrations. The approximate border between high and low levels of exposure is estimated in this review from the available relevant data, and the strengths and weaknesses of experimental models are delineated. Eventually, chronic low level exposure to these contaminants sparks cellular responses setting ground for dysfunction and disease, such as diabetes: oxidative damage is an accompanying phenomenon and not necessarily an early mechanism of toxicity.
Export Options
About this article
Cite this article as:
Adeline Jacquet, Fayçal Ounnas, Marine Lénon, Josiane Arnaud, Christine Demeilliers, Jean-Marc Moulis , Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls, Current Drug Targets 2016; 17 (12) . https://dx.doi.org/10.2174/1389450116666150531151228
DOI https://dx.doi.org/10.2174/1389450116666150531151228 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An <i>In-silico</i> Study
Current Pharmaceutical Design Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Current Pharmaceutical Design Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design The Role of LncRNA NEAT1 in Gastric Cancer: Tumor Development and Potential Therapeutic Target
Current Pharmaceutical Design Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy
Current Drug Metabolism Moving Beyond Tyrosine Hydroxylase to Define Dopaminergic Neurons for Use in Cell Replacement Therapies for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets [<sup>99m</sup>Tc(CO)<sub>3</sub>]<sup>+</sup> and [<sup>99m</sup>TcO<sub>2</sub>]<sup>+</sup> Radiolabeled Cyclic Melanotropin Peptides for Melanoma SPECT Imaging
Current Radiopharmaceuticals The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV
Mini-Reviews in Medicinal Chemistry